Treatment initiation for parkinson's disease in Australia 2013-2018 : a nation-wide study

Show full item record



Koponen , M , Bell , J S , Lalic , S , Watson , R , Koivisto , A M & Ilomäki , J 2022 , ' Treatment initiation for parkinson's disease in Australia 2013-2018 : a nation-wide study ' , BMC Geriatrics , vol. 22 , no. 1 , 483 .

Title: Treatment initiation for parkinson's disease in Australia 2013-2018 : a nation-wide study
Author: Koponen, Marjaana; Bell, J. Simon; Lalic, Samanta; Watson, Rosie; Koivisto, Anne M.; Ilomäki, Jenni
Contributor organization: Department of Neurosciences
University of Helsinki
HUS Internal Medicine and Rehabilitation
Geriatrian yksikkö
Date: 2022-06-03
Language: eng
Number of pages: 9
Belongs to series: BMC Geriatrics
ISSN: 1471-2318
Abstract: Background Guidelines highlight the importance of an individualized approach to treatment initiation for Parkinson's disease. Our aim was to investigate initiation of anti-Parkinson medication in Australia from 2013-2018, and to determine factors predicting choice of initial treatment. Methods Cohort of new-users (N = 4,887) of anti-Parkinson medication aged >= 40 years were identified from a 10% random representative sample of national medication dispensing data from July-2013 to June-2018. Changes in treatment initiation were examined across the whole cohort and stratified by age and sex. Results Treatment initiation was most frequent with levodopa followed by non-ergot dopamine agonists (DAs) and anticholinergics. Two thirds initiated with levodopa across the study period. Initiation with non-ergot DAs increased from 22 to 27% (rate ratio, RR 1.23, 95% confidence interval, CI 1.02-1.47) and initiation with anticholinergics decreased from 6.9% to 2.4% (RR 0.34, 95% CI 0.21-0.55) from 2013-2018. Among persons aged >= 65 years, one third of women and one fourth of men initiated on levodopa. Among women aged < 65 years, rates of treatment initiation with DAs (37%) and levodopa (37%) were similar in 2013/2014 but initiation with DA exceeded levodopa thereafter. Among men aged < 65 years, treatment initiation with levodopa (44%-49%) remained more frequent than initiation with DAs (29%-32%) throughout the study period. Conclusions Treatment initiation with levodopa was most frequent among persons aged >= 65 years, consistent with current guidelines. Whilst the value of levodopa sparing strategies is unclear, treatment initiation with DA has become increasingly common relative to levodopa among women but not among men aged < 65 years.
Subject: Antiparkinson drugs
Parkinson's disease
Sex differences
3121 General medicine, internal medicine and other clinical medicine
3112 Neurosciences
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
Treatment_initiation_for_parkinson_s_di...pdf 2.337Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record